Aficamten Shows Promise Over Metoprolol in Phase 3 MAPLE-HCM Trial for Obstructive HCM Dr. Kamal Kant Kohli17 May 2025 9:00 AM ISTTopline results were released from the phase 3 MAPLE-HCM trial, which compared aficamten with metoprolol in 175 adults with symptomatic obstructive...
FDA approves mavacamten for hypertrophic cardiomyopathy Jacinthlyn Sylvia19 Jun 2023 9:30 AM ISTBristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to...
Aficamten improves outcomes of obstructive hypertrophic cardiomyopathy Jacinthlyn Sylvia20 Jan 2023 11:30 AM ISTA new study by Martin Maron and team showed that aficamten significantly decreased left ventricular outflow tract (LVOT) gradients, and the majority...
Metoprolol Benefits Patients With Hypertrophic Obstructive Cardiomyopathy - TEMPO Trial MD Bureau29 Dec 2021 9:15 AM ISTThe complexity of hypertrophic cardiomyopathy (HCM) molecular pathophysiology and the efficacy of septal reduction therapies were combined to slow the...
Metoprolol reduces LVOT obstruction in obstructive hypertrophic cardiomyopathy: JACC Medha Baranwal22 Dec 2021 9:00 AM ISTDenmark: Treatment with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) significantly reduced left ventricular...
Bristol Myers Squibb submission for Mavacamten to treat Obstructive Hypertrophic Cardiomyopathy accepted by USFDA Ruchika Sharma21 March 2021 10:45 AM ISTPrinceton: Pharma major, Bristol Myers Squibb, has recently announced that the U.S. Food and Drug Administration (USFDA) has accepted its New Drug...
